|
|
|
| Analysis of the effect of FoxM1 expression on the proliferation and invasion related signaling pathways in intrahepatic cholangiocarcinoma based on GSEA |
| LIU Lingyun* MAO Han* HUANG Peilu CHEN Shule |
| Department of Hepatobiliary and Pancreatic Surgery, the Affiliated Hospital of Guilin Medical University, Guangxi Zhuang Autonomous Region, Guilin 541001, China |
|
|
|
Abstract Objective To compare and analyze the effects of FoxM1 expression on the proliferation and invasion-related cell signaling pathways in intrahepatic cholangiocarcinoma (ICC), and to reveal the molecular mechanism of its occurrence and development. Methods The mRNA data of 36 patients with ICC were downloaded from the TCGA database and divided into the high expression group and the low expression group according to the median of the overall FoxM1 expression value. The gene set enrichment analysis (GSEA) software was used for biological analysis. Informatics analysis to find possible differentially expressed genes between the high and low expressions of FoxM1 and related signal pathways that affect them. Real-time PCR (RT-PCR) was used to verify and compare the expression relationship of FoxM1 and P53 mRNA in ICC cell lines. Results GSEA analysis showed that there were significant differences in the expression of common gene signaling pathways such as P53 and MYC signaling pathways in the high FoxM1 expression group, while there were significant differences in the expression of FOXO signaling pathways in the low FoxM1 expression group (all FDR-Q values < 0.250). Rt-PCR results showed that the expression of P53 mRNA in HCC-9810-FOXM1 cells up-regulated by lentivirus transfection was significantly higher than that in control cells. The mRNA level of P53 in SSP-25-shFOXM1 cells down-regulated by FoxM1 was significantly lower than that in control cells (P < 0.000 1). Conclusion FoxM1 may play a broad role in the development of ICC and other different stages of evolution. Expression of FoxM1 may be related to P53, and FoxM1 in ICC may affect the P53 signaling pathway.
|
|
|
|
|
|
[1] Mejia JC，Pasko J. Primary Liver Cancers：Intrahepatic Cholangiocarcinoma and Hepatocellular Carcinoma [J]. Surg Clin North Am，2020，100（3）：535-549.
[2] Valle JW，Kelley RK，Nervi B，et al. Biliary tract cancer [J]. Lancet（London，England），2021，397（10272）：428-44.
[3] Gibiino G， Fabbri C， Fagiuoli S，et al. Defining the biology of intrahepatic cholangiocarcinoma：molecular pathways and early detection of precursor lesions [J]. Eur Revr Med Pharmacol Sci，2017，21（4）：730-741.
[4] Huang SB，Zheng CX. Gene alterations and epigenetic cha-nges in intrahepatic cholangiocarcinoma [J]. Expert Rev Anticancer Ther，2017，17（1）：89-96.
[5] Halasi M，Gartel AL. FOX（M1）news--it is cancer [J]. Mol Cancer Ther，2013，12（3）：245-254.
[6] Borhani S，Gartel L. FOXM1：a potential therapeutic target in human solid cancers [J]. Expert Opin Ther Targets，2020，1-13.
[7] Ai C，Zhang J，Lian S，et al. FOXM1 functions collaboratively with PLAU to promote gastric cancer progression [J]. J Cancer，2020，11（4）：788-794.
[8] Liu L，Wu J，Guo Y，et al. Overexpression of FoxM1 predicts poor prognosis of intrahepatic cholangiocarcinoma [J]. Aging (Albany NY)，2018，10（12）：4120-4140.
[9] Li X，Jin F，Li Y. A novel autophagy-related lncRNA prognostic risk model for breast cancer [J]. J Cell Mol Med，2021，25（1）：4-14.
[10] Mootha VK，Lindgren CM，Eriksson KF，et al. PGC-1alpha-responsive genes involved in oxidative phosphorylation are coordinately downregulated in human diabetes [J]. Nat Genet，2003，34（3）：267-273.
[11] Subramanian A，Tamayo P，Mootha VK，et al. Gene set enrichment analysis：a knowledge-based approach for interpreting genome-wide expression profiles [J]. Proc Natl Acad Sci U S A，2005，102（43）：15545-15550.
[12] Hernández Borrero LJ，El-Deiry WS. Tumor suppressor p53：Biology，signaling pathways，and therapeutic targeting [J]. Biochim Biophys Acta Rev Cancer，2021，1876（1）：188556.
[13] Di J，Zhao G，Wang H，et al. A p53/CPEB2 negative feedback loop regulates renal cancer cell proliferation and migration [J]. J Genet Genomics，2021，48（7）：606-617.
[14] Hao XL，Han F，Zhang N，et al. TC2N，a novel oncogene，accelerates tumor progression by suppressing p53 signaling pathway in lung cancer [J]. Cell Death Differ，2019， 26（7）：1235-1250.
[15] Ghosh M，Saha S，Bettke J，et al. Mutant p53 suppresses innate immune signaling to promote tumorigenesis [J]. Cancer cell，2021，39（4）：494-508.e5.
[16] Kalathil D，John S，Nair AS. FOXM1 and Cancer：Faulty Cellular Signaling Derails Homeostasis [J]. Front Onocol，2020，10（6）：26836.
[17] Wang L，Shi C，Yu J，et al. FOXM1-induced TYMS upregulation promotes the progression of hepatocellular carcinoma [J]. Cancer Cell Int，2022，22（1）：47.
[18] Kopanja D，Pandey A，Kiefer M，et al. Essential roles of FoxM1 in Ras-induced liver cancer progression and in cancer cells with stem cell features [J]. J Hepatol，2015， 63（2）：429-436.
[19] Francica P，Nisa L，Aebersold DM，et al. Depletion of FOXM1 via MET Targeting Underlies Establishment of a DNA Damage-Induced Senescence Program in Gastric Cancer [J]. Clin Cancer Res，2016，22（21）：5322-5336.
[20] Gartel AL. FOXM1 in Cancer：Interactions and Vulnerabilities [J]. Cancer Res，2017，77（12）：3135-3139.
[21] Barsotti AM，Prives C. Pro-proliferative FoxM1 is a target of p53-mediated repression [J]. Oncogene，2009，28（48）：4295-4305.
[22] Bollu LR，Shepherd J，Zhao D，et al. Mutant P53 induces MELK expression by release of wild-type P53-dependent suppression of FOXM1 [J]. NPJ Breast Cancer，2020， 6（3）：2.
[23] Tanaka N，Zhao M，Tang L，et al. Gain-of-function mutant p53 promotes the oncogenic potential of head and neck squamous cell carcinoma cells by targeting the transcription factors FOXO3a and FOXM1 [J]. Oncogene，2018，37（10）：1279-1292.
[24] Liu X，Zhang L，Thu PM，et al. Sodium cantharidinate，a novel anti-pancreatic cancer agent that activates functional p53 [J]. Sci China Life Sci，2021，64（8）：1295-310.
[25] Liebl MC，Hofmann TG. The Role of p53 Signaling in Colorectal Cancer [J]. Cancers，2021，13（9）：2125. |
|
|
|
